Supplement to the article entitled:

**The risk of multiple sclerosis relapse after yellow-fever vaccination: a self-controlled case series**

Angela Huttner\(^1,2\), Gilles Eperon\(^3\), Agustina M. Lascano\(^4\), Serge Roth\(^4\), Jean-Marc Schwob\(^3\), Claire-Anne Siegrist\(^1,5\), Patrice H. Lalive\(^4,5,6\)*

\(^1\)Center for Vaccinology, University of Geneva

\(^2\)Division of Infectious Diseases, Geneva University Hospitals

\(^3\)Division of Tropical and Humanitarian Medicine, Geneva University Hospitals

\(^4\)Department of Neurosciences, Division of Neurology, Unit of Neuroimmunology and Neuromuscular Diseases, Geneva University Hospitals, Geneva, Switzerland

\(^5\)Department of Pathology and Immunology, Faculty of Medicine, University of Geneva, Geneva, Switzerland

\(^6\)Division of Laboratory Medicine, Department of Diagnostic, Geneva University Hospitals, Geneva, Switzerland

*Corresponding author:

Division of Neurology

Geneva University Hospitals

Rue Gabrielle-Perret-Gentil 4

1205 Geneva, Switzerland

Tel. +41 22 3728318

Fax: +41 22 3728332

[patrice.lalive@hcuge.ch](mailto:patrice.lalive@hcuge.ch)
Figure S1: Study timeline, with predefined pre-exposure (PEP), exposure (ERP), and post-risk periods (PRP).

Figure S2. Study flow diagram.

YF: yellow fever; YFV: yellow-fever vaccine.